ARTICLE | Clinical News
Sepracor, UCB Pharma regulatory update
January 22, 2001 8:00 AM UTC
SEPR said that partner UCB received marketing approval in Germany for its levocetirizine non-sedating antihistamine to treat seasonal allergic rhinitis, perennial rhinitis and chronic idiopathic urtic...